Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1399-0004.1974.tb02263.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a novel radioiodinated compound for amyloid and tau deposition imaging in Alzheimer's disease and tauopathy mouse models.
Neuroimage
December 2024
Department of Radiopharmacy and Molecular Imaging, Minhang Hospital & School of Pharmacy, Fudan University, Shanghai, China; Department of Functional Brain Imaging Research, China; Department of Clinical and Experimental Neuroimaging, Centre for Development of Advanced Medicine for Dementia, National Centre for Geriatrics and Gerontology, Obu, Japan; Key Laboratory of Smart Drug Delivery, Fudan University, Ministry of Education, Shanghai, China; Institute for Small-Molecule Drug Discovery & Development, Quzhou Fudan Institute, Quzhou, China. Electronic address:
Article Synopsis
- - The study focused on a new compound called AD-DRK (I-AD-DRK) that can non-invasively identify amyloid-β and tau deposits in the brain, which are critical for diagnosing Alzheimer's disease and related disorders.
- - Researchers conducted tests using this compound in both postmortem human brains and mouse models with amyloid and tau accumulation, demonstrating its effective binding and visualization capabilities in the brain regions associated with these proteins.
- - The results showed that I-AD-DRK has strong potential as a SPECT imaging agent, offering high-contrast imaging of amyloid and tau, which could significantly help in early diagnosis and treatment of Alzheimer's disease and other tauopathies.
Discovery of F Labeled AZD5213 Derivatives as Novel Positron Emission Tomography (PET) Radioligands Targeting Histamine Subtype-3 Receptor.
Chembiochem
September 2024
Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, GA, 30322, USA.
The histamine subtype 3 (H) receptor is an important drug target in the central nervous system (CNS), and PET imaging offers a promising technique for the noninvasive evaluation of CNS disease related to the H receptor. In this study, we synthesized and evaluated the binding effects of [F]H3-2404 and [F]H3-2405 by modifying the structure of AZD5213, a selective H antagonist. These two radioligands were prepared in high radiochemical yields and displayed stability in serum.
View Article and Find Full Text PDFCharacterization of a S1PR2 specific C-labeled radiotracer in streptozotocin-induced diabetic murine model.
Nucl Med Biol
November 2023
Department of Radiology, Washington University School of Medicine, Saint Louis, MO, 63110, United States of America. Electronic address:
Background: Diabetes mellitus is a chronic progressive metabolic disorder that affects millions of people worldwide. Emerging evidence suggests the important roles of sphingolipid metabolism in diabetes. In particular, sphingosine-1-phosphate (S1P) and S1P receptor 2 (S1PR2) have important metabolic functions and are involved in several metabolic diseases.
View Article and Find Full Text PDFChemical design of radioiodinated probes with a metabolizable linkage for target-selective imaging of systemic amyloidosis.
Bioorg Med Chem
September 2023
Laboratory of Biophysical Chemistry, Kobe Pharmaceutical University, Japan. Electronic address:
Introduction: Systemic amyloidosis is a rare disease caused by the deposition of amyloid fibrils in various organs. Amyloid-targeted radiopharmaceuticals have been developed and applied to diagnose systemic amyloidosis peripherally; however, high-contrast imaging has not been achieved because of the high background signals in normal organs. To overcome this problem, we designed an amyloid-targeted radioiodinated probe 1 with a metabolizable linkage (ester bond) to release of radiolabeled metabolites (m-iodohippuric acid) in normal organs that could be rapidly excreted in the urine.
View Article and Find Full Text PDFAutoradiographic characterization of [ F]PSMA-1007 binding in rat brain.
Synapse
November 2023
Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland.
Carboxypeptidase II (CBPII) in brain metabolizes the neuroactive substance N-acetyl-L-aspartyl-L-glutamate (NAGG) to yield the elements of glutamate and N-acetyl-aspartate (NAA). In peripheral organs, CBPII is known as prostrate specific membrane antigen (PSMA), which presents an important target for nuclear medicine imaging in prostate cancer. Available PSMA ligands for PET imaging do not cross the blood-brain barrier, and there is scant knowledge of the neurobiology of CBPII, despite its implication in the regulation of glutamatergic neurotransmission.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!